USPTO Art Unit 1628 Prosecution Statistics

Art Unit Information

Art Unit: 1628
Group: 1620
Tech Center: 1600
Total Cases: 16,445
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19070930RAS INHIBITORSMarch 2025June 2025Allow310NoNo
19062331RAS INHIBITORSFebruary 2025June 2025Allow310NoNo
19053277ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENTFebruary 2025April 2025Allow200NoNo
19038532WRN INHIBITORSJanuary 2025March 2025Allow200YesNo
18905502GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERSOctober 2024February 2025Allow510NoNo
18905534GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERSOctober 2024April 2025Allow610NoNo
18905520GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERSOctober 2024April 2025Allow710NoNo
18895044PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAMSeptember 2024March 2025Allow500NoNo
18895095ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENTSeptember 2024February 2025Allow510NoNo
18892179Electronic Inhalation DeviceSeptember 2024February 2025Allow510YesNo
18271036HYDROXYPENTYL BENZOIC ACID DIESTER COMPOUND, AND PREPARATION METHOD AND PHARMACEUTICAL APPLICATION THEREOFSeptember 2024June 2025Allow2401NoNo
18794778STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRONAugust 2024March 2025Allow811YesNo
18790708PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERSJuly 2024March 2025Allow811YesNo
18784243PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERSJuly 2024April 2025Allow820NoNo
18777896USE OF ITACONATE AND ITS DERIVATIVES/ANALOGUES TO INDUCE HAIR GROWTHJuly 2024January 2025Allow611YesNo
18773435TOPICAL PEEL-OFF CREAM FOR NUMBING PAIN DURING SKIN-RELATED PROCEDURESJuly 2024May 2025Abandon1010NoNo
18764024FORMULATIONS AND METHODS FOR SKIN CARE OR HYALURONIC ACID SYNTHESISJuly 2024January 2025Allow710NoNo
18745002INHIBITION OF CRYSTAL GROWTH OF ROFLUMILASTJune 2024February 2025Allow810NoNo
18670632EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENTMay 2024March 2025Abandon1010NoNo
186685524,5-BIS(4-BROMOPHENYL)-2-(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDMay 2024July 2024Allow200NoNo
186627061-[4,5-BIS(4-CHLOROPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]-2-NAPHTHOL AS AN ANTIMICROBIAL COMPOUNDMay 2024July 2024Allow200NoNo
18653662TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFEMay 2024March 2025Allow1010NoNo
18652721COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND DISORDERSMay 2024February 2025Allow901NoNo
18646222ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024September 2024Allow501NoNo
18646306ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024October 2024Allow610NoNo
18632351FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USEApril 2024February 2025Allow1121YesNo
186315186-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDApril 2024October 2024Allow610NoNo
18621023PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDEMarch 2024September 2024Allow510YesNo
18616762NEUROACTIVE STEROIDS AND THEIR METHODS OF USEMarch 2024October 2024Allow710YesNo
18616903NEUROACTIVE STEROIDS AND THEIR METHODS OF USEMarch 2024October 2024Allow710NoNo
18616995NEUROACTIVE STEROIDS AND THEIR METHODS OF USEMarch 2024November 2024Allow710NoNo
186125632-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUNDMarch 2024September 2024Allow610NoNo
186125452-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUNDMarch 2024September 2024Allow610NoNo
18610777SOLID STATE FORMS OF MAVACAMTEN AND PROCESS FOR PREPARATION THEREOFMarch 2024January 2025Allow1031YesNo
18603816OXYSTEROLS AND METHODS OF USE THEREOFMarch 2024December 2024Allow910NoNo
18594194BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTSMarch 2024March 2025Allow1211NoNo
18594172BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTSMarch 2024November 2024Allow810NoNo
18592262USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS FOR INDUCTION AND MAINTENANCE OF FLOWFebruary 2024February 2025Allow1210YesNo
18687803BIFLAVONE COMPOUND AGAINST I-TYPE HERPES SIMPLEX VIRUS, AND PREPARATION METHOD THEREFOR AND USE THEREOFFebruary 2024August 2024Allow510NoNo
18589688BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTSFebruary 2024February 2025Allow1111NoNo
18589636BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTSFebruary 2024November 2024Allow910NoNo
18590387SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOFFebruary 2024January 2025Allow1112NoNo
185858723-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUNDFebruary 2024April 2024Allow200YesNo
18586021PYRROLO[3,2-C][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORSFebruary 2024October 2024Allow811NoNo
18586070PYRROLO[3,2-C][2,6]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORSFebruary 2024August 2024Allow610NoNo
18583643TETRACYCLINE COMPOSITIONSFebruary 2024August 2024Allow610YesNo
18444310READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATEFebruary 2024August 2024Allow610YesNo
18442061COMPOSITIONS AND METHODS FOR TREATING EPILEPSYFebruary 2024November 2024Allow911NoNo
18439517SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITYFebruary 2024May 2025Abandon1521NoNo
18437732TREATMENT OF MAJOR DEPRESSIVE DISORDERFebruary 2024June 2025Abandon1601NoNo
184368334-CHLORO-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2- YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024May 2024Allow400YesNo
184370076-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDFebruary 2024August 2024Allow610NoNo
18437098APPLICATIONS FOR NICARDIPINE IN PREPARING ANTI-LUNG CANCER PRODUCTSFebruary 2024June 2025Allow1611NoNo
18432492GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERSFebruary 2024September 2024Allow710YesNo
18433196ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOFFebruary 2024September 2024Allow701YesNo
184301381-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDFebruary 2024October 2024Abandon900NoNo
184301341-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDFebruary 2024April 2024Allow300NoNo
184301311-CYCLOPROPYL-6-FLUORO-7-(4-((5-(4-METHOXYBENZYLIDENEAMINO)-2-THIOXO-1,3,4- THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3- CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDFebruary 2024August 2024Allow610NoNo
18429339TOPICAL NALOXONE COMPOSITIONS AND METHODS FOR USING THE SAMEJanuary 2024February 2025Abandon1311NoNo
18429417METHODS OF REDUCING THE PRODUCTION OF GREENHOUSE GASES FROM ANIMALSJanuary 2024November 2024Allow1020YesNo
184260953-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
184260803-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024March 2024Allow200NoNo
18425761LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGSJanuary 2024July 2024Allow610NoNo
18417252COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJanuary 2024December 2024Allow1121NoNo
18413666ACID ADDITION SALTS OF BENZIMIDAZOLE DERIVATIVEJanuary 2024March 2025Allow1411NoNo
184127653-(1-(3-(DIMETHYLAMINO)PROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDIN-2-OL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow810NoNo
184127613-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUNDJanuary 2024March 2024Allow200NoNo
18411139COMBINATION THERAPY FOR TREATING CANCERJanuary 2024June 2025Abandon1701NoNo
18405907COMBINATION COMPOSITIONJanuary 2024September 2024Allow910NoNo
18400944ETHYL [4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]ACETATE AS AN ANTIMICROBIAL COMPOUNDDecember 2023April 2024Allow300NoNo
18573439APPLICATION OF CB-839 IN PREPARATION OF DRUG FOR INHIBITING CORNEAL NEOVASCULARIZATION (CNV)December 2023July 2024Allow710YesNo
18391876ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3December 2023March 2025Abandon1510NoNo
18393055TREATMENT OF AVASCULAR OR HYPOVASCULAR MICRO-TUMORSDecember 2023March 2025Abandon1510NoNo
18390195MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USINGDecember 2023June 2024Allow610YesNo
18390228MULTI-SUBSTITUENT PSILOCYBIN DERIVATIVES AND METHODS OF USINGDecember 2023June 2024Allow610YesNo
18545961POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATIONDecember 2023June 2025Allow1810YesNo
18545754USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORINGDecember 2023February 2025Abandon1410NoNo
18540651METHODS OF TREATING CANCER WITH DRUGSDecember 2023July 2024Allow710NoNo
18538065USE OF OUABAIN ANTAGONISTS TO INHIBIT VIRAL INFECTIONDecember 2023May 2025Abandon1710NoNo
18537729PYRROLO[3,2-C]ISOQUINOLINE-2,3-DIONE COMPOUNDS AS CK2 INHIBITORSDecember 2023February 2025Allow1420YesNo
185333453-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPOPAN-1-AMINE AS AN ANTIMICROBIAL COMPOUNDDecember 2023April 2024Allow401NoNo
185333593-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPOPAN-1-AMINE AS AN ANTIMICROBIAL COMPOUNDDecember 2023March 2024Allow300NoNo
18532133METAL SALTS AND USES THEREOFDecember 2023November 2024Allow1110NoNo
185312402-AMINO-4-(4-BROMOPHENYL)-6-METHOXYPYRIDINE-3,5-DICARBONITRILE AS AN ANTIBACTERIAL COMPOUNDDecember 2023September 2024Abandon911NoNo
18529368LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITORDecember 2023September 2024Abandon1011YesNo
18529497NOVEL WATER SOLUBLE NANO-SIZED IMINE RU(III) COMPLEX BASED ON 4-AMINOBENZENE SODIUM SULPHONATE FOR BIOMEDICAL APPLICATIONSDecember 2023March 2024Allow302YesNo
18529147Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition DisorderDecember 2023June 2025Abandon1820YesNo
18517062Method Of Treating Major Depressive DisorderNovember 2023February 2025Allow1520NoNo
18518292METHOD OF MODULATING TIGIT AND PD-1 SIGNALLING PATHWAYS USING 1,2,4-OXADIAZOLE COMPOUNDSNovember 2023March 2024Allow410NoNo
18516174PROCASPASE COMBINATION THERAPY FOR GLIOBLASTOMANovember 2023June 2025Allow1820YesNo
18512564HBV INHIBITOR AND ITS USENovember 2023March 2025Allow1621NoNo
185114263,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) AS AN ECOFRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)November 2023March 2024Allow410NoNo
185118003,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) AS AN ECOFRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)November 2023May 2024Allow620NoNo
185113187H-PYRIDO[4',3':4,5]PYRROLO[2,3-C][1,7]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSNovember 2023February 2025Allow1520YesNo
18509800COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATIONNovember 2023January 2025Abandon1410NoNo
18389456AGONISTS OF EPHA AND THEIR USESNovember 2023June 2025Abandon1911NoNo
18507797HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONSNovember 2023January 2025Abandon1401NoNo
18388707BENZOFURO[3,2-C]CHROMEN-6-ONE COMPOUNDS AS ANTIBACTERIAL AGENTSNovember 2023March 2024Allow410NoNo
183879184,5-BIS(4-BROMOPHENYL)-2-(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDNovember 2023April 2024Allow611NoNo
18388070RAPIDLY ACCELERATED FIBROSARCOMA (RAF) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USENovember 2023June 2024Allow700YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1628.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
332
Examiner Affirmed
246
(74.1%)
Examiner Reversed
86
(25.9%)
Reversal Percentile
17.9%
Lower than average

What This Means

With a 25.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1812
Allowed After Appeal Filing
305
(16.8%)
Not Allowed After Appeal Filing
1507
(83.2%)
Filing Benefit Percentile
2.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1628 - Prosecution Statistics Summary

Executive Summary

Art Unit 1628 is part of Group 1620 in Technology Center 1600. This art unit has examined 16,445 patent applications in our dataset, with an overall allowance rate of 49.7%. Applications typically reach final disposition in approximately 29 months.

Comparative Analysis

Art Unit 1628's allowance rate of 49.7% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1628 receive an average of 2.00 office actions before reaching final disposition (in the 66% percentile). The median prosecution time is 29 months (in the 47% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.